PROMIS NEUROSCIENCES INC

Company Overview

ProMIS Neurosciences (PMN) is a development-stage biotechnology company that applies a computation-driven discovery platform (licensed from the University of British Columbia) to generate antibodies, intrabodies and peptide vaccines that selectively target toxic, misfolded protein conformations implicated in neurodegenerative diseases. Its lead therapeutic, PMN310 (anti-amyloid-β oligomer), cleared an IND in May 2023, completed Phase 1a and initiated the Phase 1b PRECISE‑AD trial in late 2024; other programs target misfolded TDP‑43, alpha‑synuclein and additional neurodegeneration targets. Operations are research‑intensive and lean (eight staff as of Dec 31, 2024), heavily dependent on contract research organizations, academic collaborators and outsourced cGMP manufacturing; the company has not generated product revenue and is highly valuation‑sensitive to clinical and partnering milestones.

Executive Compensation Practices

Given ProMIS’s development-stage profile and the MDA disclosures, executive pay is likely heavily equity‑linked and milestone‑oriented: R&D progress (INDs, trial enrollment, GLP tox outcomes, and interim/topline readouts) and successful partnering/licensing are the primary drivers of long‑term pay value. Filings show materially increased share‑based compensation and legal/severance charges, consistent with a compensation mix that leans on stock options/RSUs to conserve cash while aligning management to trial and financing milestones; discretionary cash bonuses are likely constrained by liquidity. With persistent cash burn, going‑concern uncertainty, and substantial potential dilution from outstanding warrants (~57.1M warrants; ~$92.4M potential proceeds noted), boards at similar biotechs tend to tie incentive vesting to de‑risking events (e.g., Fast Track designation, no ARIA safety signal, enrollment/catalyst timelines) and include severance protections to recruit/retain leadership in a high‑execution environment.

Insider Trading Considerations

Insider activity at ProMIS should be interpreted in the context of frequent financing events and significant warrant overhang: management and large shareholders may exercise options/warrants and sell shares to meet tax and liquidity needs, potentially creating short‑term selling pressure around financings (recent July 2024 PIPE and July 2025 financings). Material clinical milestones (INDs, FDA Fast Track on July 21, 2025, interim/topline PRECISE‑AD data expected 2026) create clear blackout/event windows—insider trades near these catalysts warrant heightened scrutiny for timing and use of pre‑arranged 10b5‑1 plans. Because the company is small, individual insider trades can materially impact the float and price; regulatory reporting (insider forms, cross‑jurisdiction rules) and internal policies should constrain opportunistic trading, but watch for patterns of option exercises followed by immediate sales and for large trades by warrant holders that could be liquidity‑driven rather than sentiment‑driven.